Clinical trials: Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.
- Trial name
- NCT02683928
- Testing
- GBR 830
- Where
- 17 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Ichnos Sciences SA
Atopic Dermatitis
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
- Trial name
- ALLEVIAD (NCT02525094)
- Testing
- MEDI9929
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- MedImmune LLC
Atopic Dermatitis
Effects of Abrocitinib Treatment on Skin Barrier Function
Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.
- Trial name
- AbroSkib (NCT05140239)
- Testing
- No Intervention
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Prof. Dr. Stephan Weidinger
Atopic Dermatitis
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD)…
- Trial name
- CHRONOS (NCT02260986)
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 148 sites in United States, Australia and 12 more
- Volunteers
- 740 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
This is a 32-week, open-label, exploratory study with a 4-week screening period, 16-week treatment phase designed to investigate dupilumab's effect on skin barrier function as measured by TEWL before and after STS in…
- Trial name
- PELISTAD CN (NCT05680298)
- Testing
- Dupilumab
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Dermatitis, Atopic Dermatitis
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT02087943
- Testing
- Apremilast
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 191 people
- Sponsor
- Amgen
Atopic Dermatitis
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of lebrikizumab administered subcutaneously (SC) in adult participants with persistent moderate to severe atopic dermatitis (AD) who…
- Trial name
- NCT02340234
- Testing
- Lebrikizumab, TCS Cream
- Where
- 74 sites in United States, Australia and 12 more
- Volunteers
- 212 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Atopic Eczema
Narrowband UVB for Children With Moderate to Severe Atopic Eczema
To assess prospectively, the response of moderate to severe atopic eczema to a standard course of narrowband ultraviolet B phototherapy by using validated objective and subjective scoring systems.
- Trial name
- NCT01569906
- Testing
- Narrowband Ultraviolet B phototherapy
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Royal Victoria Infirmary
Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy…
- Trial name
- NCT07235384
- Testing
- ZL-1503
- Where
- 12 sites in Australia, China and 1 more
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Atopic Dermatitis (AD)
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07336940
- Testing
- ENV-294 Capsule
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
- Trial name
- ATLAS (NCT03533751)
- Testing
- Etokimab
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 302 people
- Sponsor
- AnaptysBio, Inc.
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.
- Trial name
- NCT02576938
- Testing
- Baricitinib, Triamcinolone (Optional)
- Where
- 13 sites in United States, Japan
- Volunteers
- 124 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A Multi-center, Open, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of FURESTEM-AD inj. in Patients with Moderate to Severe Chronic Atopic Dermatitis Who Participated in a Placebo Group in K0102 Clinical Trial…
- Trial name
- NCT04087863
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 99 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07800104
- Testing
- QX4533
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- QuantX Biosciences, Inc.
Moderate to Severe Atopic Dermatitis
A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD).
- Trial name
- NCT07558668
- Testing
- SYX-5219 Oral Capsule
- Where
- 14 sites in United States, Bulgaria and 4 more
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Sitryx Therapeutics Ltd
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.
- Trial name
- NCT06767540
- Where
- 28 sites in China
- Volunteers
- 198 people
- Sponsor
- Akeso